Adding to the ever-growing list of newly discovered bacterial immune systems, we have characterized the mechanisms of an ...

By deducing the possible ancient forms of a bacterial enzyme, OIST scientists have resurrected one of its ancestral versions, ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

This study provides a valuable look at genome-wide RNaseA-resistant RNA-DNA interactions in human embryonic stem cells. The research indicated that RNase treatment maintained long-range RNA-chromatin ...

4′-Fluorouridine works against RNA-dependent RNA polymerase, an enzyme that helps viruses assemble RNA. The compound has a ...

Computational biologists from the National University of Singapore (NUS) have uncovered how RNA splicing—a crucial process ...

Researchers investigate the influence of Mettl1 on energy metabolism and the maturation of heart cells after birth.

Dominique Verhelle is co-founder and CEO of the Brighton-based company NextRNA Therapeutics, which uses long non-coding RNA ...

We can already tinker with human DNA to treat diseases. But being able to edit RNA allows for even more precision – and fewer ...

Belgium mRNA specialist Quantoom Biosciences and biologics manufacturing specialist Univercells inked a partnership deal with ...

ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.